SujathaHariharanMD

Oncology • Austell, GA

Physician

Join to view full profile

Are you Dr. Hariharan?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 51 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1700 Hospital South Dr
Suite 300
Austell, GA 30106
Phone+1 770-944-2830

Fax+1 678-581-7170
Is this information wrong?

Summary

Dr. Sujatha Hariharan, MD is an oncologist in Austell, Georgia. She is currently licensed to practice medicine in Georgia, Colorado, and Pennsylvania. She is affiliated with WellStar Cobb Hospital, WellStar Kennestone Hospital, and WellStar Paulding Hospital.

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2003 - 2006
Temple University HospitalResidency, Internal Medicine, 2000 - 2003
St. George's University School of MedicineClass of 2000

Certifications & Licensure

GA State Medical License 2006 - 2025
CO State Medical License 2003 - 2007
PA State Medical License 2001 - 2003
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Publications & Presentations

PubMed

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee S, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Ca...> ;Br. J. Cancer. 2015-06-30
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S,...> ;Br. J. Cancer. 2014-06-10
Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal ce...
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Martell B, Hariharan S, Figlin RA> ;J. Clin. Oncol.. 2011-03-01
100 citations
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Phar...
Stephen Leong, Roger B. Cohen, Daniel L. Gustafson, Corey J. Langer, D. Ross Camidge, Kristin Padavic, Lia Gore, Margaret Smith, Laura Q M Chow, Margaret von Mehren, C...> ;Journal of Clinical Oncology. 2009 Sep 10
Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States.
Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S> ;J. Clin. Oncol.. 2009-05-20
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in...
O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG> ;Cancer Chemother. Pharmacol.. 2009-02-01
Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial.
Hariharan S, Szczylik C, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee S, Carteni G, Gore ME> ;J. Clin. Oncol.. 2008-05-20
Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC).
Porta C, Szczylik C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee S, Carteni G, Hariharan S, Gore ME> ;J. Clin. Oncol.. 2008-05-20
Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC).
Szczylik C, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee S, Carteni G, Hariharan S, Gore ME> ;J. Clin. Oncol.. 2008-05-20
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients w...
Hariharan, S.,Gustafson, D.,Holden, S.,McConkey, D.,Davis, D.,Morrow, M.,Basche, M.,Gore, L.,Zang, C.,O'Bryant, C. L.,Baron, A.,Gallemann, D.,Colevas, D.,Eckhardt, S. G.> ;Ann. Oncol.. 2007 Aug 19
2 citations
Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine.
Sujatha Hariharan, Carolyn H. Welsh> ;Chest. 2007 Jun 1
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study.
Chow LQ, Eckhardt SG, Gustafson DL, O'Bryant C, Hariharan S, Diab S, Fox NL, Corey A, Padavic K, Brown M, Cohen RB> ;J. Clin. Oncol.. 2006-06-20
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small c...
Hanna NH, Einhorn L, Sandler A, Langer C, Hariharan S, Ansari R, Ellis P, Byrne M, Wang B, Bunn P> ;J. Clin. Oncol.. 2005-06-01
Idiopathic intracranial hypertension, empty sella turcica and polycystic ovary syndrome--a case report.
Au Eong KG, Hariharan S, Chua EC, Leong S, Wong MC, Tseng PS, Yong VS> ;Singapore Med J. 1997-03-01
Join now to see all

Press Mentions

Decision Left to School Board After Cobb Health Officials Approve Measures on Masks in SchoolsSeptember 7th, 2021

Hospital Affiliations

Northside HospitalAtlanta, Georgia
WellStar Cobb HospitalAustell, Georgia
WellStar Douglas HospitalDouglasville, Georgia
WellStar Kennestone HospitalMarietta, Georgia
Wellstar North Fulton HospitalRoswell, Georgia
WellStar Paulding HospitalHiram, Georgia